Specialties – Page 48

MODICA: A Mitochondrial Peptide Shielding the Heart Against Doxorubicin-Induced Cardiotoxicity

By MedXY 09/06/2025

MODICA, a mitochondrial sORF-encoded peptide, protects cardiac function from doxorubicin toxicity by inhibiting VDAC oligomerization, reducing apoptosis and fibrosis, highlighting a novel cardioprotective therapeutic target.

Cardiology news Specialties

Comparing Health Status Outcomes of PCI and CABG in Chronic Coronary Disease: Insights from ISCHEMIA

By MedXY 09/05/2025

The ISCHEMIA trial reveals that both PCI and CABG improve health status over conservative management in chronic coronary disease, with CABG offering superior angina relief at 1 year but similar benefits to PCI by 3 years.

Cardiology news Pathology & Lab Medicine Specialties

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

By MedXY 09/05/2025

This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the SEQUOIA-HCM trial.

Clinical Updates Gastroenterology news Psychiatry Specialties

Increased Risk of Psychiatric Disorders in Patients with Microscopic Colitis: Insights from a Nationwide Swedish Cohort Study

By MedXY 09/05/2025

A comprehensive Swedish study reveals that patients with microscopic colitis face a significantly higher risk of developing psychiatric disorders such as depression and anxiety, underscoring the importance of holistic clinical management.

Clinical Updates Critical Care Emergency Medicine Gastroenterology news Specialties

Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis

By MedXY 09/05/2025

This multicentre trial shows sequential use of COX-2 inhibitors parecoxib and imrecoxib significantly reduces severe acute pancreatitis (SAP) incidence, shortens organ failure duration, lowers local complications, and decreases 30-day mortality, with a good safety profile.

Gastroenterology news Specialties

Enhanced Diagnostic and Prognostic Utility of the China-CLIF Framework for Acute-on-Chronic Liver Failure Across Diverse Aetiologies

By MedXY 09/04/2025

A large multicohort study demonstrates that the China-CLIF framework outperforms existing criteria in diagnosing and predicting mortality in acute-on-chronic liver failure across all major aetiologies, with global applicability.

Clinical Updates Infectious Diseases news Specialties

Decoding Immune Dynamics in HBV-Related Acute-on-Chronic Liver Failure: Insights from Single-Cell Multimodal Analysis

By MedXY 09/04/2025

This longitudinal single-cell multiomics study delineates the evolving immune landscape in HBV-ACLF, identifying key immune cell subsets and signaling pathways that drive disease progression and highlight potential therapeutic targets for precision medicine.

Clinical Updates Infectious Diseases news

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY 09/04/2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatments.

Clinical Updates Gastroenterology news

Assessing the Risk of High-Risk Neoplasia Post-Polypectomy in Adults Below and Above 50 Years: Implications for Surveillance Guidelines

By MedXY 09/04/2025

This study compares the risk of recurrent high-risk neoplasia after polypectomy in adults younger and older than 50, revealing similar elevated risks, supporting the extension of existing surveillance guidelines to younger adults.

Clinical Updates news Oncology

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

By MedXY 09/04/2025

A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.

Cardiology news Specialties

Spontaneous Intramuscular Hematoma in a Patient with Warfarin Therapy: A Case Report

By MedXY 09/04/2025

A 75-year-old male on warfarin presented with spontaneous thigh swelling and pain, diagnosed as spontaneous intramuscular hematoma, successfully managed with supportive care and warfarin reversal.

Clinical Updates Family Medicine & Nutrition Neurology news Specialties

Genotype-Specific Metabolic Insights and Mediterranean Diet Impact on Dementia Risk and Cognitive Health

By MedXY 09/04/2025

This article explores how genetic variants, plasma metabolites, and Mediterranean diet adherence interplay in modulating dementia risk and cognitive function, highlighting precision nutrition approaches for Alzheimer’s disease prevention.

$Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis$

Allergy & Immunology Clinical Updates Rheumatology Specialties

Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis

By MedXY 09/04/2025

A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicated by lupus nephritis.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

By MedXY 09/04/2025

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan's efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.

news Oncology Pathology & Lab Medicine Specialties

Circulating Tumor DNA as a Biomarker to Guide Timing of CDK4/6 Inhibitor Therapy in Advanced ER+ HER2− Breast Cancer

By MedXY 09/04/2025

Pretreatment circulating tumor DNA levels can predict which patients with advanced ER-positive, HER2-negative breast cancer benefit more from first-line CDK4/6 inhibitor therapy, supporting personalized treatment strategies.

news Oncology Specialties

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

By MedXY 09/04/2025

A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast cancer survivors.

Medical News news Oncology Specialties

Unmasking Brain Cancer’s Sugar Secret: How Glioblastoma Hijacks Glucose to Fuel Tumor Growth and Resist Therapy

By MedXY 09/04/2025

A groundbreaking Nature study reveals how glioblastoma reprograms glucose metabolism, exploiting environmental serine to accelerate growth and resist treatment, offering new metabolic targets for personalized therapies.

Family Medicine & Nutrition Medical News Neurology news Specialties

Precision Nutrition: Can the Mediterranean Diet Reduce Alzheimer’s Risk in APOE4 Carriers?

By MedXY 09/04/2025

A large prospective study reveals that adherence to a Mediterranean diet significantly lowers dementia risk, especially in individuals carrying two copies of the APOE4 gene associated with Alzheimer’s disease, highlighting the potential of genetics-informed dietary strategies.

Gastroenterology news Specialties

Unveiling the Role of FODMAPs in Functional Dyspepsia: Efficacy of Low FODMAP Diet and Personalized Reintroduction

By MedXY 09/04/2025

A 6-week low FODMAP diet improves symptoms in functional dyspepsia/Postprandial Distress Syndrome, with variable individual triggers including glucose, though mucosal integrity remains unchanged.

news Oncology Specialties

Immunosuppressive Roles of Tumour-Infiltrating B Cells in Intrahepatic Cholangiocarcinoma and Implications for Chemoimmunotherapy Outcomes

By MedXY 09/04/2025

This article reviews the immunosuppressive mechanisms of tumour-infiltrating B cells in intrahepatic cholangiocarcinoma (iCCA), their impact on prognosis, and potential to enhance chemoimmunotherapy efficacy by restoring B-cell function and promoting tertiary lymphoid structures.